mani
effect
vaccin
avail
protect
human
infecti
diseas
howev
develop
vaccin
difficult
pathogen
remain
challeng
exampl
vaccin
human
immunodefici
viru
hiv
respiratori
syncyti
viru
rsv
still
develop
furthermor
exist
vaccin
requir
improv
efficaci
eg
vaccin
bordetella
pertussi
influenza
virus
mycobacterium
tuberculosi
plasmodium
speci
caus
malaria
addit
new
infecti
diseas
sever
acut
respiratori
syndrom
ebola
viru
diseas
continu
emerg
requir
new
vaccin
prevent
epidem
also
therapeut
vaccin
diseas
cancer
need
lack
knowledg
pathogen
requir
protect
immun
often
hamper
applic
system
biolog
develop
vaccin
system
vaccinolog
import
tool
enhanc
insight
immun
respons
induc
candid
vaccin
identif
earli
correl
alan
aderem
defin
system
biolog
comprehens
quantit
analysi
manner
compon
biolog
system
interact
function
time
space
execut
interdisciplinari
team
investig
definit
readili
appli
studi
respons
vaccin
approach
often
label
unbias
broad
sometim
even
word
holist
use
howev
true
certain
extent
defin
research
object
alreadi
introduc
bia
often
analyt
techniqu
use
describ
next
section
address
object
fig
usual
also
limit
avail
materi
exampl
preclin
studi
use
mice
amount
blood
collect
limit
wherea
clinic
studi
mainli
bodi
fluid
use
although
biopsi
mucos
lavag
sometim
avail
also
time
essenti
paramet
system
vaccinolog
studi
kinet
relat
repeat
sampl
limit
human
review
describ
current
develop
techniqu
form
pillar
system
vaccinolog
discuss
implement
system
vaccinolog
vaccin
research
develop
chain
decad
rna
analysi
appli
studi
evolv
quantit
polymeras
chain
reaction
method
like
microarray
sequenc
rnaseq
applic
rang
assess
transcript
profil
whole
tissu
blood
purifi
cell
recent
even
singl
contrast
convent
transcriptom
analysi
result
loss
tissu
cell
transcriptom
vivo
analysi
allow
us
monitor
mrna
express
situ
live
cell
transcriptom
complet
genom
unbias
rel
straightforward
offer
servic
mani
contract
laboratori
gene
express
level
kinet
provid
inform
involv
gene
follow
howev
mrna
often
effector
molecul
need
translat
protein
mrna
level
often
correl
protein
content
one
studi
report
mice
condit
mrna
transcript
correl
protein
end
transcriptom
profil
vaccin
research
serv
excel
tool
find
potenti
marker
respons
subsequ
need
confirm
protein
cellular
level
novel
method
cellular
index
transcriptom
epitop
sequenc
tri
overcom
translat
challeng
combin
parallel
target
singl
cell
protein
marker
unbias
transcriptom
profil
obtain
specif
inform
gene
express
cellular
phenotyp
complet
addit
mrna
profil
investig
role
microrna
becom
relev
given
role
contrari
transcriptom
proteom
encompass
effector
exert
control
immun
respons
receptor
ligand
enzym
hormon
even
structur
protein
detect
foreign
substanc
determin
ident
cell
commun
messag
cell
tissu
profil
subset
protein
peptid
involv
immun
respons
term
immunoproteom
import
understand
vaccin
work
last
three
decad
mass
spectrometri
ms
proteom
emerg
essenti
tool
profil
immunoproteom
term
protein
identif
protein
dynam
interact
hunt
et
pioneer
analysi
immunogen
peptid
present
molecul
major
histocompat
complex
mhc
sinc
mani
studi
profil
human
leucocyt
antigen
hla
ligand
repertoir
use
immunoprecipit
techniqu
subsequ
ligand
identif
find
new
antigen
lead
understand
concept
immunogen
apart
target
infecti
mhc
ligandom
analysi
also
appli
exampl
cancer
recent
studi
howev
shown
plethora
peptid
even
complex
expect
due
format
peptid
sequenc
ie
splice
variant
epitop
estim
epitop
compris
splice
addit
profil
epitop
repertoir
assess
antigen
determin
interact
antibodi
high
signific
elucid
immun
respons
vaccin
develop
vaccin
sinc
epitop
often
conform
even
discontinu
identif
complex
current
possibl
use
silico
tool
instrument
improv
ms
support
softwar
tool
ms
use
versatil
tool
determin
epitop
area
antibodi
bind
opuni
et
comprehens
review
approach
map
epitop
bind
one
exampl
interact
interact
analysi
interactom
rapidli
develop
identifi
type
interact
new
class
reagent
great
potenti
like
reagent
compound
stabil
transient
interact
format
coval
bond
physiolog
condit
also
allow
unambigu
identif
spatial
distribut
peptid
interact
protein
base
presenc
characterist
report
ion
mass
spectra
repres
intramolecular
intermolecular
liu
et
al
show
good
correl
protein
data
obtain
chemic
ms
use
reagent
data
microscopi
purifi
protein
assembl
addit
also
identifi
hela
cell
lysat
protein
domain
lack
illustr
great
potenti
strategi
identifi
interact
detect
interact
mandatori
amino
acid
interact
area
reactiv
secret
protein
play
essenti
role
commun
immun
cell
immun
secretom
consist
wide
rang
cytokin
tumor
necrosi
factor
interferon
interleukin
multiplex
immunoassay
elisa
method
target
predefin
protein
secretom
base
antibodi
contrast
newli
develop
proteom
method
like
bioorthogon
amino
acid
tag
boncat
target
full
repertoir
secret
protein
although
limit
vitro
experi
boncat
assay
amino
acid
replac
analogu
eg
methionin
replac
azidohomoalanin
azido
moieti
allow
purif
excret
low
abund
newli
synthes
protein
cell
cultur
medium
use
amino
acid
modif
affect
structur
function
protein
alter
protein
synthesi
rate
cell
combin
multiplex
technolog
base
tandem
mass
tag
tmt
n
leucin
dileu
tag
reagent
sampl
multiplex
singl
run
unbias
identif
rel
quantif
de
protein
limit
proteom
lay
fact
like
transcriptom
depend
avail
qualiti
annot
protein
databas
eg
number
annot
gene
protein
sensit
current
gener
mass
spectromet
high
could
improv
reach
level
achiev
exampl
quantit
polymeras
chain
reaction
howev
describ
ms
current
use
character
wide
rang
immunolog
mechan
context
infect
vaccin
system
vaccinolog
approach
limit
common
applic
transcriptom
proteom
novel
techniqu
applic
often
appli
tabl
exampl
metabolom
technolog
studi
metabol
pathway
biolog
system
metabolom
cover
small
molecul
intermedi
usual
dalton
da
molecular
weight
highli
dynam
catabol
anabol
process
cell
mani
immunolog
studi
metabolom
integr
part
system
vaccinolog
predict
biomark
evalu
vaccin
untarget
metabolom
analysi
requir
mani
differ
sampl
prepar
procedur
analyt
tool
identifi
metabolit
ga
chromatographi
liquid
chromatographi
capillari
electrophoresi
ms
fourier
transform
infrar
spectroscopi
nuclear
magnet
reson
frequent
use
combin
studi
metabolom
although
limit
precis
accuraci
improv
accuraci
precis
specif
assay
obtain
use
target
metabolom
strategi
chemic
ident
analyt
known
context
system
vaccinolog
convent
assay
neither
high
throughput
unbias
remain
necessari
confirm
hypothes
histolog
still
common
method
confirm
influx
locat
immun
cell
tissu
result
infect
immun
howev
visual
cell
tissu
section
continu
improv
better
immunoimag
confoc
microscopi
ex
vivo
assay
elisa
flow
cytometri
appli
identifi
quantifi
specif
cell
subset
well
activ
state
function
cytokin
product
prolifer
immunolog
techniqu
studi
respons
also
becom
power
flow
cytometri
equip
improv
exampl
combin
measur
amount
protein
per
cell
flow
cytometri
visual
local
within
cell
microscopi
imag
flow
also
fluoresc
label
becom
avail
increas
number
marker
investig
simultan
flow
cytometri
enabl
identif
special
often
rare
subset
exampl
innat
cell
play
crucial
role
pathogen
recognit
influenc
magnitud
direct
adapt
immun
specif
subtyp
cell
innat
lymphoid
cell
respect
adapt
immun
respons
abil
identifi
rare
subset
mainli
focus
circul
cell
precursor
well
effector
memori
cytometri
mass
spectrometri
cytof
use
isotop
instead
fluoresc
label
label
therebi
almost
abolish
spectral
overlap
seen
fluoresc
dye
expand
number
marker
measur
simultan
even
exampl
van
unen
et
identifi
immun
subset
human
mucos
immun
system
addit
opportun
sort
specif
subset
cell
popul
also
singl
cell
combin
analysi
isol
cell
ad
yet
anoth
dimens
lymphocyt
epitop
specif
necessarili
extrem
divers
fight
wide
array
possibl
pathogen
accomplish
random
sever
recombinatori
event
addit
random
chang
lymphocyt
ontogeni
exampl
number
differ
antibodi
human
produc
outnumb
b
lymphocyt
human
analysi
enabl
detail
interrog
broad
techniqu
also
reveal
prime
might
alway
predict
preferenti
expans
also
play
import
illustr
enhanc
understand
lymphocyt
respons
lead
identif
novel
earli
marker
efficaci
vaccin
also
use
evalu
hypothes
respect
epitop
deriv
studi
describ
former
paragraph
moreov
current
knowledg
respect
hla
specif
also
enabl
predict
epitop
silico
decreas
time
need
epitop
often
conform
current
knowledg
yet
enabl
silico
predict
extent
epitop
analysi
complex
vaccin
bind
investig
use
gel
electrophoresi
western
blot
pinpoint
immunogen
subsequ
peptid
array
appli
investig
immunodomin
epitop
discov
abil
isol
singl
subsequ
dna
sequenc
immunoglobulin
gene
set
greatli
impact
depth
understand
respect
antibodi
sort
combin
clone
enabl
isol
specif
antibodi
abl
neutral
pathogen
includ
rare
antigen
characterist
special
interest
antibodi
broadli
among
highli
variabl
virus
bind
conserv
region
exampl
found
influenza
hemagglutinin
ha
subtyp
upon
infect
well
gener
shift
focu
immunogen
epitop
conserv
region
howev
prove
challeng
design
vaccin
induc
strong
respons
region
challeng
respect
design
vaccin
induc
broadli
neutral
antibodi
hiv
influenza
viru
extens
review
corti
exampl
region
might
need
remov
conserv
epitop
might
easili
access
prevent
antibodi
bind
natur
target
anoth
point
attent
focu
increas
immunogen
lead
decreas
safeti
exampl
antibodi
long
charg
region
enabl
bind
occlud
site
pathogen
mediat
pathogen
neutral
also
like
igg
antibodi
level
serv
correl
protect
tradit
context
system
vaccinolog
antibodi
quantiti
also
function
increasingli
investig
antibodi
may
inhibit
function
antibodi
enhanc
diseas
facilit
viru
entri
cell
howev
antibodi
may
still
function
could
impact
protect
diseas
neutral
antibodi
instanc
interact
antibodi
constant
domain
fc
receptor
interact
determin
two
characterist
antibodi
subclass
irrevers
antibodi
glycosyl
fast
revers
exampl
impact
affin
fc
glycosyl
profil
antibodi
chang
upon
vaccin
wherea
glycosyl
profil
total
igg
affect
interestingli
despit
differ
glycosyl
level
popul
differ
part
profil
induc
vaccin
similar
shown
influenza
howev
differ
vaccin
formul
induc
differ
glycosyl
like
also
influenc
adjuv
present
formul
either
directli
via
cytokin
though
biolog
implic
differ
yet
clear
recent
develop
system
serolog
demonstr
multipl
paramet
antibodi
respons
igg
subtyp
antibodi
glycosyl
among
other
influenc
antibodi
function
therefor
vaccin
one
difficulti
system
approach
amount
data
statist
evalu
visual
extract
meaning
conclus
major
challeng
requir
multipl
tool
new
technolog
system
vaccinolog
metabolom
may
requir
differ
statist
bioinformat
analysi
strategi
compar
transcriptom
proteom
data
set
describ
ren
et
visual
data
full
genom
proteom
initi
perform
tool
appli
eg
heatmap
venn
diagram
network
analysi
eg
allow
visual
numer
individu
data
point
group
also
cluster
relat
data
point
addit
gener
multipl
data
set
enabl
comparison
immun
respons
induc
differ
vaccin
unbias
hierarch
stochast
neighborhood
embed
hsne
enabl
us
visual
data
cellular
composit
million
cell
detail
although
graph
provid
easier
perspect
trend
data
set
design
provid
inform
biolog
function
individu
data
point
develop
data
mine
tool
fig
given
scientist
handl
translat
data
set
descript
relev
biolog
allow
investig
involv
mutual
interact
pathway
process
cell
type
tool
focus
pathway
analysi
includ
gene
ontholog
go
kyoto
encyclopedia
gene
genom
kegg
biogp
involv
cell
differ
stage
cell
activ
also
led
develop
special
databas
specif
research
topic
exampl
innatedb
contain
data
innat
immun
interferom
focus
cemitool
use
analys
discoveri
function
discoveri
analysi
repertoir
receptor
sequenc
vdjviz
appli
routin
analysi
qualiti
control
sequenc
immun
vdjdb
design
annot
receptor
repertoir
databas
evolv
expand
continu
base
novel
data
scientif
insight
technolog
depend
choic
data
mine
tool
outcom
result
might
differ
howev
within
human
vaccin
research
demonstr
differ
outcom
data
either
analyz
use
tool
base
prior
knowledg
case
netanalyst
platform
unbias
tool
diablo
addit
gener
knowledg
understand
larg
data
set
use
comput
system
biolog
studi
predict
host
immun
antigen
point
view
tool
wide
appli
predict
novel
tool
enabl
us
predict
capac
epitop
induc
data
gather
silico
prior
simultan
laboratori
studi
confirm
role
host
biomark
antigen
epitop
vaccin
respons
discoveri
phase
system
approach
implement
investig
vaccin
composit
especi
interest
complex
vaccin
fig
exampl
transcriptom
andor
proteom
approach
appli
strain
gener
inactiv
vaccin
provid
detail
inform
protein
composit
specif
proport
immunogen
protein
techniqu
subsequ
use
process
develop
verifi
whether
product
similar
produc
larger
scale
instanc
demonstr
pertussi
inform
relationship
cultiv
condit
composit
final
vaccin
consider
enhanc
process
optim
vaccin
efficaci
addit
reveal
key
process
paramet
subsequ
tightli
monitor
make
process
consist
therebi
eventu
vaccin
releas
easier
studi
vaccin
respons
discoveri
phase
system
vaccinolog
method
use
studi
mechan
action
vaccin
adjuv
vitro
well
experiment
anim
fig
vitro
assay
allow
gain
inform
magnitud
direct
innat
respons
lack
possibl
studi
coher
interact
innat
adapt
immun
respons
especi
transit
innat
adapt
respons
lot
immunolog
inform
still
miss
main
focu
system
vaccinolog
respons
respons
infect
also
great
interest
enabl
discoveri
potenti
marker
mechan
involv
protect
immun
unwant
immunolog
effect
immun
evas
fig
system
biolog
assist
investig
interact
look
pathogen
behavior
clearanc
infect
natur
infect
sometim
induc
effect
protect
eg
mump
may
serv
benchmark
vaccin
wherea
pathogen
may
display
immun
evas
suppress
respons
one
would
like
avoid
respons
approach
instanc
use
investig
respons
term
diseas
investig
look
respons
pathogen
b
pertussi
cours
b
pertussi
infect
investig
mice
unravel
molecular
cellular
signatur
effect
result
indic
b
pertussi
infect
induc
helper
type
cell
mucos
iga
respons
preced
prolong
respons
broad
pathogen
recognit
earli
gene
signatur
subsequ
recruit
addit
infect
led
enhanc
activ
pulmonari
innat
immun
cell
marker
indic
recruit
promis
marker
respons
ideal
confirm
human
b
pertussi
challeng
compar
network
analysi
two
data
set
pulmonari
molecular
signatur
preced
effector
cell
b
pertussi
compar
signatur
induc
upon
pulmonari
immun
novel
outer
membran
vesicl
pertussi
vaccin
omvpv
network
analysi
demonstr
similar
gene
pathway
involv
respons
intens
kinet
respons
differ
respons
howev
result
induct
mucos
immun
better
protect
compar
subcutan
vaccin
administr
system
approach
also
use
investig
innat
respons
exampl
respons
induc
vitro
studi
perform
investig
respons
induc
alum
salt
use
proteom
studi
dendrit
cell
respons
follow
lipopolysaccharid
stimul
use
transcriptom
extens
vitro
studi
provid
insight
novel
marker
pathway
cell
subset
activ
adjuv
yet
complex
interact
immun
respons
requir
vivo
studi
also
address
mosca
et
conduct
one
first
studi
mice
better
understand
adjuv
alum
cpg
odn
respons
profil
muscl
site
inject
provid
compar
inform
plain
adjuv
respons
fact
cpg
elicit
stronger
system
innat
respons
compar
alum
other
studi
respons
adjuv
combin
antigen
might
also
influenc
immun
respons
olafsdottir
et
determin
molecular
signatur
induc
mice
four
clinic
test
vaccin
adjuv
alum
use
tuberculosi
vaccin
candid
model
antigen
transcriptom
analysi
signatur
follicular
helper
tfh
germin
center
gc
respons
found
enhanc
adjuv
vaccin
compar
antigen
alon
use
similar
combin
adjuv
santoro
et
appli
system
vaccinolog
demonstr
recal
innat
respons
follow
boost
modul
use
adjuv
primari
immun
lindqvist
et
focus
specifi
molecular
signatur
mice
induc
mucos
adjuv
vaccin
sexual
transmit
infect
relev
anim
model
studi
infect
alway
avail
case
applic
system
approach
vaccin
studi
provid
valuabl
inform
mechan
action
candid
vaccin
et
al
unravel
transcriptom
activ
marker
human
myeloid
plasmacytoid
dendrit
cell
upon
stimul
vaccin
candid
hivaid
base
vector
subsequ
memori
respons
demonstr
strout
et
abl
link
earli
specif
gene
transcript
relat
activ
type
interferon
respons
magnitud
neutral
antibodi
titer
immun
tetraval
dengu
vaccin
primat
part
develop
novel
outer
membran
vesicl
pertussi
vaccin
omvpv
respons
investig
mice
extens
proteom
approach
antibodi
profil
use
determin
distinct
antibodi
specif
subclass
distribut
induc
differ
pertussi
transcriptom
cytokin
profil
demonstr
reduc
respons
potenti
lead
less
advers
effect
omvpv
compar
classic
pertussi
vaccin
maintain
vaccin
investig
effect
rout
immun
protect
immun
respons
induc
subcutan
pulmonari
administr
omvpv
mice
studi
demonstr
improv
mucos
immun
therefor
protect
b
pertussi
pulmonari
immun
final
term
vaccin
safeti
mizukami
et
appli
rat
model
predict
safeti
consist
influenza
vaccin
wang
et
investig
blood
gene
signatur
primat
immun
seven
market
experiment
vaccin
isol
marker
vaccin
efficaci
safeti
wherea
overlap
trend
marker
efficaci
found
vaccin
marker
found
correl
advers
effect
predict
marker
found
exploratori
studi
describ
previou
section
appli
subsequ
clinic
studi
moreov
system
vaccinolog
analys
also
use
clinic
studi
obtain
better
insight
safeti
efficaci
fig
howev
knowledg
clinic
studi
system
vaccinolog
perform
assess
signatur
correl
advers
effect
fever
seizur
project
biovacsaf
system
approach
appli
investig
marker
correl
vaccin
safeti
human
anim
model
potenti
provid
novel
investig
conduct
studi
human
investig
vaccin
candid
ebola
malaria
rt
tuberculosi
ebola
natur
killer
nk
cell
independ
correl
antibodi
titer
suggest
could
potenti
target
influenc
anderson
et
investig
transcriptom
profil
blood
healthi
volunt
follow
immun
novel
vaccin
adjuv
receptor
agonist
high
respond
base
serum
antibodi
contain
modul
gene
express
nk
cell
wherea
modul
gene
relat
myeloid
cell
monocyt
integrin
cell
surfac
interact
detect
low
respond
signatur
enabl
vaccin
respons
distinguish
earli
phase
perhap
even
allow
steer
immun
respons
low
respond
adjust
vaccin
phase
random
control
trial
use
unadjuv
inactiv
influenza
vaccin
effect
adjuv
respons
serum
cytokin
antibodi
titer
gene
express
level
investig
led
novel
insight
antigen
process
present
marker
neutrophil
reveal
correl
serum
level
prolifer
nk
interestingli
predict
protect
induc
malaria
rt
immun
nk
cell
correl
neg
wherea
posit
correl
detect
molecular
signatur
plasma
nuclear
find
indic
differ
combin
may
induc
differ
immun
non
effect
respons
vaccin
licens
introduc
market
surveil
studi
perform
monitor
vaccin
safeti
efficaci
larger
popul
fig
point
vaccin
life
cycl
correl
protect
surrog
thereof
sometim
known
howev
mechan
action
often
underexpos
system
approach
phase
routin
appli
far
know
valid
method
complex
expens
ad
valu
yet
proven
convincingli
howev
pioneer
studi
demonstr
vaccin
efficaci
yellow
fever
influenza
vaccin
could
predict
earli
stage
immun
analyz
molecular
yellow
fever
vaccin
enhanc
level
specif
gene
express
profil
blood
obtain
day
vaccin
predict
level
antibodi
titer
usual
obtain
day
immun
thu
induc
signific
time
advantag
clinic
phase
regul
might
want
see
posit
classic
purpos
approach
look
earli
correl
may
valuabl
furthermor
studi
valu
compar
studi
differ
vaccin
formul
nakaya
et
compar
two
differ
vaccin
formul
trival
inactiv
influenza
vaccin
tiv
tiv
ativ
children
predict
influenza
antibodi
titer
month
vaccin
season
influenza
vaccin
across
five
consecut
season
analyz
specif
signatur
innat
immun
plasma
addit
system
biolog
approach
could
also
appli
investig
differ
vaccin
respons
differ
target
group
exampl
research
predict
vaccin
hepat
b
vaccin
elderli
gene
expos
transcriptom
signatur
immun
cellular
humor
immun
respons
season
influenza
vaccin
specif
older
obvious
surveil
studi
facilit
clinic
develop
improv
vaccin
provid
insight
gener
mechan
enhanc
futur
vaccin
develop
even
correl
protect
final
great
benefit
system
vaccinolog
studi
abil
combin
data
set
vaccin
respons
differ
pathogen
integr
network
model
reveal
detail
insight
univers
signatur
vaccin
li
et
compar
molecular
signatur
induc
five
differ
human
vaccin
specif
bacteri
viral
infect
could
predict
antibodi
respons
indic
investig
respons
singl
pathogen
lead
univers
marker
serv
benchmark
vaccin
develop
new
emerg
diseas
also
support
desir
data
obtain
publicli
avail
open
access
futur
larg
system
vaccinolog
implement
differ
phase
vaccin
develop
chain
becom
relev
approach
field
vaccinolog
recent
progress
system
vaccinolog
led
success
initi
aditec
provid
novel
gene
express
method
analyz
biomark
tuberculosi
well
studi
safeti
immunogen
novel
vaccin
tuberculosi
achiev
maximum
vaccin
efficaci
safeti
futur
vaccin
research
focu
target
group
even
develop
person
system
vaccinolog
approach
appli
investig
differ
vaccin
respons
healthi
adult
specif
target
group
infant
elderli
investig
respons
system
vaccinolog
led
trend
gather
massiv
amount
data
go
deep
investig
everi
molecul
singl
cell
acquir
larg
data
set
far
easier
extract
novel
relev
inform
data
furthermor
amount
data
constantli
increas
especi
combin
data
set
differ
origin
gene
versu
protein
versu
cell
requir
equal
advanc
tool
data
visual
ii
translat
content
knowledg
understand
forc
dialogu
vaccin
develop
bioinformat
expert
futur
implement
artifici
intellig
could
assist
data
process
data
visual
onlin
public
may
becom
interact
allow
reader
scroll
exampl
immun
respons
induc
immun
time
summari
system
vaccinolog
becom
valuabl
tool
phase
vaccin
develop
chain
link
predict
immun
respons
beforehand
howev
still
difficult
small
import
step
current
taken
toward
applic
insight
creat
system
vaccinolog
recent
studi
show
applic
system
vaccinolog
especi
interest
investig
complex
danger
pathogen
ebola
viru
hiv
plasmodium
spp
tuberculosi
phase
studi
challeng
even
even
investig
heterolog
effect
vaccin
induc
promis
chang
call
inclus
system
vaccinolog
earli
possibl
vaccin
develop
chain
better
understand
vaccin
work
other
enabl
effici
vaccin
develop
proport
design
phase
lead
improv
vaccin
evalu
earli
phase
therebi
reduc
time
cost
rr
er
hm
bm
gk
wrote
review
author
declar
compet
interest
